Gubra A/S/DKr GUBRA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Gubra A/S
Gubra A/S is a biotechnology company based in Denmark, focusing on pre-clinical contract research and drug discovery. It specializes in the development of peptide-based therapeutics and provides services in areas such as obesity, diabetes, and NASH (non-alcoholic steatohepatitis). The company was founded in 2008 and operates from its headquarters in Hørsholm, Denmark. Gubra differentiates itself through its integrated approach combining histology, imaging, and bioinformatics to deliver comprehensive research services. Its strategic positioning leverages cutting-edge technology to support pharmaceutical companies in early-stage drug development.
- Ticker
- DKr GUBRA
- Sector
- Health
- Primary listing
- CSE
- Employees
- 330
- Headquarters
- Horsholm, Denmark
- Website
- www.gubra.dk
Gubra A/S Metrics
BasicAdvanced
kr 5B
-
-kr 11.16
0.32
-
Price and volume
Market cap
kr 5B
Beta
0.32
52-week high
kr 557.50
52-week low
kr 272.00
Average daily volume
55K
Financial strength
Current ratio
11.424
Quick ratio
10.743
Long term debt to equity
0.151
Total debt to equity
0.178
Interest coverage (TTM)
-2.47%
Profitability
EBITDA (TTM)
-191.652
Gross margin (TTM)
75.29%
Net profit margin (TTM)
-67.25%
Operating margin (TTM)
-73.07%
Effective tax rate (TTM)
-2.50%
Revenue per employee (TTM)
kr 820,000
Management effectiveness
Return on assets (TTM)
-5.89%
Return on equity (TTM)
-16.12%
Valuation
Price to revenue (TTM)
18.081
Price to book
4.75
Price to tangible book (TTM)
4.82
Price to free cash flow (TTM)
-6.146
Free cash flow yield (TTM)
-16.27%
Free cash flow per share (TTM)
-48.815
Growth
Revenue change (TTM)
-89.72%
Earnings per share change (TTM)
-110.49%
3-year revenue growth (CAGR)
10.02%
3-year earnings per share growth (CAGR)
173.82%
What the Analysts think about Gubra A/S
Analyst ratings (Buy, Hold, Sell) for Gubra A/S stock.
Analyst projections of the future price of Gubra A/S stock.
Bulls say / Bears say
A second partner-led obesity programme, BI 3034701, has advanced to Phase 2. The start earned Gubra a €10 million milestone and gives the company another potential source of future payments without Gubra leading development. (Gubra)
Gubra’s own GUB-UCN2 has entered a Phase 1/2a trial, testing whether it can reduce fat while preserving or increasing muscle, including alongside incretin drugs. If the preclinical promise translates to people, this body-composition focus could distinguish it from weight-loss treatments that also reduce lean mass. (Gubra)
Gubra reported a DKK 122.9 million operating loss in H1 2026, while revenue fell 95% to DKK 126.3 million. The comparison was distorted by the prior year’s large AbbVie upfront payment, but the figures still show how uneven partnership income can make reported results. (Gubra)
GUB-UCN2’s muscle-preservation proposition is still unproven in people: the programme has only just started Phase 1/2a, and its first human data are not expected until H1 2027. Delayed or disappointing clinical results could therefore undermine a major part of Gubra’s growth case. (Gubra)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
Gubra A/S Financial Performance
Revenues and expenses
Gubra A/S Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Gubra A/S
AllUSDEUR
Fund name | Fund size | DKr GUBRA weighting |
|---|---|---|
iShares Healthcare Innovation€2B78 | $1.2B | 0.03% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.03% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.03% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.02% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.